Key result
Review details assessment, pathophysiology, and prenatal therapy for fetal AV block affecting ~1 in 20,000 births.
This review summarizes the assessment, pathophysiology, and potential prenatal therapies for fetal congenital complete atrioventricular block.
Potential prenatal therapies for fetal AV block warrant cautious consideration; leaves open need for prospective trials to guide practice.
Congenital complete atrioventricular (AV) block occurs in approximately 1 in 20,000 live births and is known to result in significant mortality and morbidity both during fetal life and postnatally. Complete AV block can occur as a result of an immune or a non-immune mediated process. Immune mediated AV block is a multifactorial disease, but is associated with the trans-placental passage of maternal autoantibodies (anti-Ro/SSA and/or anti-La/SSB). These autoantibodies attach to and subsequently damage the cardiomyocytes and conduction tissue in susceptible fetuses. In this report, we examine the evidence in reference to means of assessment, pathophysiology, and potential prenatal therapy of atrioventricular block.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2014) conducted a review in Congenital complete atrioventricular block. This review examines the evidence regarding the assessment, pathophysiology, and potential prenatal therapy of fetal atrioventricular block, which occurs in approximately 1 in 20,000 live births.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: